SuperworthLemaitre Vascular LMAT
- Market cap
- $1.9B
- PE
- 29.6×
- 10y median 42.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 7.4×
- EV/EBIT
- 22.6×
- Revenue, 12 months
- $262.4M
- +12% on a year ago
- Net margin
- 25.0%
- Free cash flow yield
- 3.8%
Lemaitre Vascular trades at 29.6× trailing earnings, cheaper than 87% of the last ten years. Revenue was $262.4M over the last twelve months, up 12% on a year earlier with a 25% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $47.4M+22% | $48.9M+19% | $53.5M+14% | $55.8M+11% | $54.8M+16% | $55.7M+14% | $59.9M+12% | $64.2M+15% | $61M+11% | $64.5M+16% | $66.6M+11% | $70.4M+10% | |
| Cost of revenue | $16.6M+19% | $15.6M+5% | $16.8M+4% | $17.4M−4% | $17.6M+6% | $17.1M+10% | $18.5M+10% | $19.3M+11% | $15.1M−15% | $18.3M+7% | $18.2M−2% | $19.6M+2% |
| Gross profit | $30.8M+23% | $33.3M+28% | $36.7M+19% | $38.5M+20% | $37.2M+21% | $38.6M+16% | $41.4M+13% | $45M+17% | $46M+24% | $46.2M+20% | $48.4M+17% | $50.8M+13% |
| R&D | $4.2M+22% | $4.4M+22% | $4.1M+6% | $4.3M−5% | $3.7M−13% | $3.6M−17% | $4.1M+0% | $3.5M−17% | $3M−19% | $3.5M−2% | $4.1M−1% | $4.8M+37% |
| SG&A | $17.4M+13% | $18.7M+20% | $20.7M+10% | $19.8M+10% | $20.4M+17% | $22.1M+18% | $24.7M+19% | $25.3M+28% | $22.7M+11% | $23.8M+8% | $26.6M+8% | $25.5M+1% |
| $9.2M+49% | $10.2M+47% | $11.9M+51% | $14.4M+52% | $13.1M+43% | $12.9M+26% | $12.6M+6% | $16.1M+12% | $20.3M+55% | $18.8M+47% | $17.8M+41% | $20.4M+26% | |
| Interest expense | n/a | n/a | $0 | $0 | $0 | $205K | $1.3M | $1.3M | $1.3M | $1.3M+533% | $1.3M+1% | $1.3M+0% |
| Pre-tax income | $9.8M+60% | $11.3M+45% | $12.8M+60% | $15.5M+50% | $14.6M+48% | $14M+24% | $14.2M+11% | $18.1M+17% | $22.6M+55% | $20.3M+45% | $19.7M+38% | $22.2M+23% |
| $2.3M+236% | $2.8M+31% | $2.9M+47% | $3.7M+66% | $3.4M+47% | $2.8M−0% | $3.2M+11% | $4.3M+17% | $5.2M+53% | $4.7M+66% | $4M+24% | $5.1M+20% | |
| Net income | $7.5M+38% | $8.5M+50% | $9.9M+64% | $11.8M+46% | $11.1M+49% | $11.2M+32% | $11M+11% | $13.8M+17% | $17.4M+56% | $15.6M+39% | $15.7M+42% | $17.1M+24% |
| $0.33+32% | $0.38+52% | $0.44+63% | $0.52+44% | $0.49+49% | $0.49+29% | $0.48+9% | $0.60+15% | $0.75+53% | $0.68+39% | $0.68+42% | $0.74+23% | |
| 22.5M+1% | 22.5M+1% | 22.6M+1% | 22.7M+1% | 22.8M+2% | 22.9M+2% | 22.9M+2% | 22.9M+1% | 24.4M+7% | 23M+0% | 23M+1% | 24.5M+7% |
EPS, diluted: 5 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Lemaitre Vascular's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| NVSTEnvista | $3.8B | 40.7× | 27.9× | 1.3× | +12% | 3.3% | |
| Peer median | $1.8B | 38.9× | 47.3× | 2.8× | +11% | 4.3% |
More on Lemaitre Vascular
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 80Medical instruments and supplies stocks with the highest profit margins
- #6of 23Medical instruments and supplies stocks cheapest against their own PE history
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .